Oxford Nanopore Technolo... Share Discussion Threads

[rampmeister] 24/7/2024 15:03

Looks like we are breaking out of 12 month downtrend established since last August. I’m only up around 14% but thinking of increasing up to mid weight holding providing current price level is maintained.

RM

[seball] 24/7/2024 08:08

Buy and hold don't give up your shares cheaply. This is ridiculously undervalued. Good luck all

[seball] 24/7/2024 07:07

No change in guidance and continued confidence to meet 2024 outlook. This will be taken as good news and share price will continue to rise over coming months. This is a sitting duck for a takeover once anti takeover shares expire in October.Good luck all

[bamboo2] 24/7/2024 07:04

24 July 2024

Oxford Nanopore Technologies plc

Half Year Trading Update

· Trading in-line with both revenue and gross margin guidance in the face of challenging end-markets

· Building commercial momentum heading into the second half reinforces confidence; full year 2024 and medium-term guidance reaffirmed

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or "the Group"), the company delivering a new generation of molecular sensing technology based on nanopores, today provides a trading update for the six months ended 30 June 2024 ahead of results, which will be published on 3 September 2024.

The Group expects to report Life Sciences Research Tools (LSRT) revenue for the six months ended 30 June 2024 of approximately £84 million (H1 2023: £86.0 million), broadly flat year-on-year at constant currency; marginally down (2%) on a reported basis, including foreign exchange headwinds. Underlying[1] LSRT revenue, grew by 12.4% on a constant currency basis year-on-year. Growth for the first half of 2024 is in-line with expected 2024 phasing.

Underlying growth has been strongest across the PromethION franchise[2], across all product lines. Underlying growth was delivered across each region, and it was strongest across EMEAI and APAC, with commercial momentum building for the second half, supported by new product launches, a number of new and expanded contracts, and a step up in sales team productivity in the second quarter.

Gross margin for the first half is expected to show year-on-year improvement, despite foreign exchange headwinds, and remains on track to meet the Group's full year 2024 guidance.

Outlook

Full year 2024 guidance remains unchanged:

- LSRT revenue growth is expected to be between 6 and 15% on a constant currency basis and underlying revenue growth is expected to be between 20 and 30% on a constant currency basis. The Group continues to expect FY 2024 revenue to be second half weighted, with an approximate 45:55 split.

- Gross margin is expected to be approximately 57%.

All medium-term (FY 2027) guidance is unchanged.



Gordon Sanghera, Chief Executive Officer, commented:

"Our first half performance is in-line with our expectations. We delivered robust underlying revenue growth, despite a challenging macroeconomic backdrop.



"We enter the second half in a strong position; new contract wins coupled with the increased productivity of our sales teams in the second quarter reinforces our confidence in our full year 2024 outlook. In addition, the launch of new products from our regulated pipeline, including GridION Q-Line and ElysION, our sample-to-answer automated sequencing solution, will drive adoption in new clinical and applied markets in the near and medium-term."

[bamboo2] 23/7/2024 10:55

steeple, a test of the breakout level is extremely common.
From a technical pov, we certainly didn't want a pesky little gap left this low down!

[steeplejack] 23/7/2024 10:18

There was 50/- on offer on quote and deal first thing around 121p.'Mark it up,suck them in' seems to be the order of the day and tracking the recent daily price movements has been a tricky exercise.Yet its not really a concern,the fundamentals suggest the stock is oversold and perhaps the trading update tomorrow will consolidate the recent uptrend.The company is very conscious of its poor rating by all accounts.

[bamboo2] 23/7/2024 08:37

Price gapped up this morning from 120.4 eod close yesterday.

Lets get that filled for now.

[bamboo2] 23/7/2024 08:22

RNS NON 23/7/2024
Oxford Nanopore Technologies plc

Oxford Nanopore and Plasmidsaurus announce collaboration and multi-year, multi-million dollar contract expansion

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, and Plasmidsaurus, the LA-based company that introduced overnight whole-plasmid sequencing, today announce a new strategic collaboration to advance plasmid sequencing beyond legacy methods, and an expanded multi-year, multi-million dollar global contract.

Plasmidsaurus' whole-plasmid sequencing is used by researchers and industry professionals around the world for a broad spectrum of applications, from basic research to industrial applications, gene therapy, vaccine development, genetic engineering and more. Its sequencing capabilities are based on Oxford Nanopore's real-time, long-read sequencing technology, which has enabled Plasmidsaurus to set new standards for quality and speed, delivering overnight results and richer datasets that unlock more accurate, comprehensive, and reliable insights.

The extension of the existing contract will see the collaboration continue to take share of a fast-growing estimated $1.5B market opportunity in synthetic biology as nanopore-based sequencing continues to displace traditional methods, such as Sanger, for plasmid sequencing. Founded in 2021, Plasmidsaurus has since opened nine labs in three countries and is expanding its global network of 660 dropboxes and labs in key biotech hubs, including new locations in the US, Europe, and Asia. Plasmidsaurus became an Oxford Nanopore customer in 2021.

As strategic collaborators going forward, Oxford Nanopore and Plasmidsaurus also intend to co-develop new technologies, reagents, and applications beyond plasmid sequencing, including microbial and gene therapy use cases, to best meet evolving market needs, providing further market share opportunities.

Gordon Sanghera, CEO of Oxford Nanopore commented:

"By collaborating with Plasmidsaurus, we are advancing the fields of synthetic biology and biotechnology through the unique capabilities of nanopore technology that are not possible with legacy methods. Our joint efforts will drive significant market growth and deliver best-in-class sequencing services to a global audience."

[steeplejack] 22/7/2024 15:44

24 July 2024Half year 2024 trading update3 September 2024Half year results for the six months ended 30 June 2024Optimism ahead of Wednesday's update

[stamford hill] 22/7/2024 15:40

If it closes around this level it will be a confirmed change of trend. Will wait for the inevitable pullback (hopefully)to pick up the kids and buy in..

[apple53] 22/7/2024 11:27

And we're through. Let's see if we can hold. Next minor resistance 122?

[apple53] 22/7/2024 11:15

Well I make that the 6th attempt just now. SOOO tempted to trade it again. Probably would have done if it weren't for stamp.

[brucie5] 19/7/2024 15:26

Lols. I'm sure you're not the only one!

[steeplejack] 19/7/2024 12:47

Interesting to note that my initial buy-in price remains the uncanny reliable top of the current trading range :)

[apple53] 18/7/2024 11:38

Darn it. Maybe 6th time lucky

[apple53] 18/7/2024 11:07

For a moment I thought You had bought 100k, Seball.....

So this is the fifth attempt to break through 115-116, and given yesterday's higher low it is promising.

[seball] 18/7/2024 10:59

100k shares just bought for above ask.. Bodes well... Buy

[chc15] 18/7/2024 08:48

Bought some at 110 near close yesterday. This has some interesting shareholders, they must be pressing the Co for some action.

[steeplejack] 17/7/2024 11:19

Need to break through 115p.Proved to be a resistance level a month or so back but its building nicely.After such underperformance,its not going to take much to see a sharp recovery all things considered.

[chc15] 17/7/2024 10:51

damn, was looking to buy, new brokers always mean something!

[seball] 17/7/2024 09:27

Break out on large volume. 150p next stop. BUY

[eeza] 16/7/2024 15:44

Large churn today.

[trickydicky1] 16/7/2024 07:26

Why not Cavendish in preparation for a relisting on AIM?

[seball] 16/7/2024 07:05

Sounds like preparation for listing in US. That should put a rocket up the share price.

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, today announces the appointment of Berenberg as joint corporate broker alongside Citigroup Global Markets Limited and J.P. Morgan Securities plc (which conducts its UK investment banking business as J.P. Morgan Cazenove) with immediate effect